Recent Investment Analysts’ Ratings Changes for Moderna (MRNA)

Several analysts have recently updated their ratings and price targets for Moderna (NASDAQ: MRNA):

• 8/25/2026 – Moderna was upgraded by Wolfe Research from “underperform” to “peer perform”.
• 8/24/2026 – Moderna had its price target raised by Barclays PLC from $48.00 to $125.00. They now have an “equal weight” rating on the stock.
• 8/21/2026 – Moderna had its price target raised by JPMorgan Chase & Co. from $40.00 to $77.00. They now have an “underweight” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by UBS Group AG from $50.00 to $150.00. They now have a “neutral” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by Morgan Stanley from $39.00 to $89.00. They now have an “equal weight” rating on the stock.
• 8/19/2026 – Moderna had its “neutral” rating reaffirmed by Morgan Stanley.
• 8/19/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $67.00 to $120.00. They now have a “neutral” rating on the stock.
• 8/19/2026 – Moderna had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $130.00 price target on the stock.
• 8/19/2026 – Moderna was given a new $135.00 price target by Loop Capital.
• 8/19/2026 – Moderna had its “buy” rating reaffirmed by Brookline Capital Markets.
• 8/19/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 8/19/2026 – Moderna was upgraded by Bank of America Corporation from “underperform” to “neutral”.
• 8/19/2026 – Moderna was upgraded by William Blair from “market perform” to “outperform”.
• 8/3/2026 – Moderna had its “overweight” rating reaffirmed by UBS Group AG.
• 8/3/2026 – Moderna had its “overweight” rating reaffirmed by Piper Sandler.
• 8/3/2026 – Moderna had its price target raised by Citigroup Inc. from $41.00 to $60.00. They now have a “neutral” rating on the stock.
• 7/21/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $49.00 to $67.00. They now have a “neutral” rating on the stock.
• 7/20/2026 – Moderna had its “underperform” rating reaffirmed by Wolfe Research. They now have a $25.00 price target on the stock.
• 7/8/2026 – Moderna had its price target raised by Morgan Stanley from $33.00 to $39.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Royal Bank Of Canada from $38.00 to $45.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Bank of America Corporation from $34.00 to $38.00. They now have an “underperform” rating on the stock.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by corporate insiders.

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.